Moreover, the finding that GNAS copy number gain can markedly enhance tumor cell proliferation implied that an inhibitor therapy targeting CDK6 may be effective for PIT1 lineage patients harboring GNAS copy number gain. Here, GNAS is linked to neoplasm.